Eilean Therapeutics Unveils In Vivo Results for TE205 MALT1 Degrader Targeting Ulcerative Colitis Eilean Therapeutics showcases its innovative drug TE205 at a major conference, demonstrating significant potential for treating ulcerative colitis through unique mechanisms.

Eilean Therapeutics Unveils In Vivo Results for TE205 MALT1 Degrader Targeting Ulcerative Colitis #United_States #Las_Vegas #Eilean_Therapeutics #MALT1 #TE205